Latest news with #McKesson
Yahoo
4 days ago
- Business
- Yahoo
What to Expect From McKesson's Q1 2026 Earnings Report
Valued at a market cap of $89.5 billion, McKesson Corporation (MCK) is a healthcare services and information technology company headquartered in Irving, Texas. It provides pharmaceutical distribution, medical supplies, healthcare technology, and support services to pharmacies, hospitals, and biopharma companies. MCK is expected to announce its fiscal Q1 earnings for 2026 after the market closes on Wednesday, Aug. 6. Ahead of this event, analysts expect this healthcare company to report a profit of $8.25 per share, up 4.7% from $7.88 per share in the year-ago quarter. The company has topped Wall Street's earnings estimates in three of the last four quarters, while missing on another occasion. In Q4 2025, MCK's EPS of $10.12 outpaced the forecasted figure by 3.2%. More News from Barchart Dear Google Stock Fans, Mark Your Calendars for July 23 Dear UnitedHealth Stock Fans, Mark Your Calendars for July 29 Peter Thiel Is Betting Big on This Ethereum Treasury Stock. Should You Buy Shares Now? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For fiscal 2026, analysts expect McKesson to report a profit of $37.25 per share, up 12.7% from $33.05 per share in fiscal 2025. Furthermore, its EPS is expected to grow 12.1% year-over-year to $41.76 in fiscal 2027. Shares of MCK have rallied 22.6% over the past 52 weeks, outpacing both the S&P 500 Index's ($SPX) 10.5% uptick and the Health Care Select Sector SPDR Fund's (XLV) 10.4% decline over the same time frame. On May 8, McKesson delivered mixed Q4 results, and its shares closed up marginally in the following trading session. The company's total revenue improved 18.9% year-over-year to $90.8 billion, driven by strength in its pharmaceutical distribution division, expansion of its oncology platform, and continued growth in biopharma solutions. However, the top-line figure fell short of the consensus expectations by 3.1%. Nonetheless, due to higher revenue, lower tax rate, and strong operational growth across the business, MCK's adjusted EPS of $10.12 advanced 63.8% from the year-ago quarter and exceeded the consensus estimates by 3.2%. Wall Street analysts are highly optimistic about MCK's stock, with a "Strong Buy" rating overall. Among 16 analysts covering the stock, 12 recommend "Strong Buy" and four suggest "Hold.' The mean price target for MCK is $785.47, implying a 9.7% premium from the current levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Business Insider
15-07-2025
- Business
- Business Insider
McKesson CEO sells $13.7M in common stock
In a regulatory filing, McKesson (MCK) disclosed that its CEO Brian Tyler sold 19.4K shares of common stock on July 11th in a total transaction size of $13.7M. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
12-07-2025
- Business
- Yahoo
Cencora, Inc. (COR): If It Was Down, I'd Say 'Double Down And Buy,' Says Jim Cramer
We recently published . Cencora, Inc. (NYSE:COR) is one of the stocks Jim Cramer recently discussed. Cencora, Inc. (NYSE:COR) is an American pharmaceutical and healthcare services provider. It is a rare stock in its peers that is in the green this year. Cencora, Inc. (NYSE:COR)'s shares have gained 32.30% year-to-date as the firm has benefited from being insulated against tariffs and the Most Favored Nation drug policy. The strong backdrop has also allowed it to raise its earnings guidance. In May, Cencora, Inc. (NYSE:COR) raised its profit per share guidance to $15.70 and $15.95 from an earlier $15.30 to $15.60. In his comments, Cramer shared that he'd buy the stock even if it dipped by 50%: 'No I mean look it's not the hospitals which always win and it's certainly not the middlemen. I mean if you told me Cencora was down 50%, I'd say why don't you double down and buy a lot.' Previously, the CNBC host discussed Cencora, Inc. (NYSE:COR) and its peers in detail: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum. I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don't live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what's known as the Most-Favored-Nation pricing for Medicare… While we acknowledge the potential of COR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-07-2025
- Business
- Yahoo
McKesson Corporation (MCK): If It Was Down, I'd Say 'Fill Her Up,' Says Jim Cramer
We recently published . McKesson Corporation (NYSE:MCK) is one of the stocks Jim Cramer recently discussed. McKesson Corporation (NYSE:MCK) is one of the largest healthcare services providers in America. In his earlier comments about the company, Cramer discussed that regulatory challenges could continue to deal significant blows to the firm and its peers. McKesson Corporation (NYSE:MCK)'s stock has gained 26% year-to-date despite falling by 8.9% in April after the Liberation Day tariff announcements. The stock has performed well due to multiple catalysts, such as strong earnings reports and dividend increases. Here is what Cramer said about McKesson Corporation (NYSE:MCK): 'No I mean look it's not the hospitals which always win and it's certainly not the middlemen. . .And if you told me McKesson was down three quarters, I'd say well fill her up.' Previously, he mentioned McKesson Corporation (NYSE:MCK) shares and the potential of government action: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum. A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy. I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don't live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what's known as the Most-Favored-Nation pricing for Medicare… While we acknowledge the potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
04-07-2025
- Business
- Yahoo
Is It Worth Investing in McKesson (MCK) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about McKesson (MCK). McKesson currently has an average brokerage recommendation (ABR) of 1.47, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.47 approximates between Strong Buy and Buy. Of the 17 recommendations that derive the current ABR, 13 are Strong Buy, representing 76.5% of all recommendations. Check price target & stock forecast for McKesson here>>> While the ABR calls for buying McKesson, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. Looking at the earnings estimate revisions for McKesson, the Zacks Consensus Estimate for the current year has increased 0.2% over the past month to $37.25. Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for McKesson. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, the Buy-equivalent ABR for McKesson may serve as a useful guide for investors. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
